Heron Therapeutics (NASDAQ:HRTX) Now Covered by Analysts at HC Wainwright

Equities researchers at HC Wainwright began coverage on shares of Heron Therapeutics (NASDAQ:HRTX) in a report issued on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $6.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 185.71% from the stock’s current price.

Several other research analysts also recently commented on HRTX. Wall Street Zen raised Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th.

Heron Therapeutics Stock Performance

HRTX opened at $2.10 on Monday. The firm has a market cap of $320.38 million, a P/E ratio of -11.67 and a beta of 1.15. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93. The business has a 50 day moving average price of $2.02 and a 200 day moving average price of $1.87.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $38.90 million during the quarter, compared to the consensus estimate of $37.08 million. As a group, analysts anticipate that Heron Therapeutics will post -0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Heron Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nicolet Advisory Services LLC bought a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $25,000. RFP Financial Group LLC acquired a new stake in Heron Therapeutics in the 1st quarter valued at $26,000. Argent Advisors Inc. acquired a new stake in Heron Therapeutics in the 4th quarter valued at $31,000. Focus Partners Wealth bought a new stake in Heron Therapeutics during the 4th quarter worth about $31,000. Finally, Valeo Financial Advisors LLC boosted its stake in shares of Heron Therapeutics by 34.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company’s stock worth $40,000 after buying an additional 4,619 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.